Long-Term Benefit of Empagliflozin on Life Expectancy in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease.
Document Type
Journal Article
Publication Date
10-9-2018
Journal
Circulation
Volume
138
Issue
15
Inclusive Pages
1599-1601
DOI
10.1161/CIRCULATIONAHA.118.033810
Keywords
Aged; Aged, 80 and over; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus; Female; Glucosides; Humans; Life Expectancy; Male; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Survival Analysis; Time Factors; Treatment Outcome
Publisher
Lippincott Williams & Wilkins
Recommended Citation
Claggett, B., Lachin, J. M., Hantel, S., Fitchett, D., Inzucchi, S. E., Woerle, H. J., George, J. T., & Zinman, B. (2018). Long-Term Benefit of Empagliflozin on Life Expectancy in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease.. Circulation, 138 (15). http://dx.doi.org/10.1161/CIRCULATIONAHA.118.033810
Peer Reviewed
1
